Japan targets “faster than FDA” medtech approvals, but reimbursement issues remain
This article was originally published in Clinica
Executive Summary
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent groundbreaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, AdvaMed senior vice-president of global strategy and analysis